Russ, thanks for the clarification, but I think that it is far from clear as to the total $ expenditure in these vax trials and whether their will be a HSV 2b trial and if so is it fully funded. Also what about the HPV Phase 1 trial and will require it require additional funds. IMO there are still many unanswered questions regarding the funding of the vax trials.
Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-76
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.22 |
Change
0.740(6.45%) |
Mkt cap ! $258.3M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $12.25 | $11.49 | $395.2K | 33.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $11.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.22 | 127 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |